Tactile Systems Technology Reports Strong Full Year 2024 Earnings
February 20, 2025 - 16:31
Tactile Systems Technology has announced its financial results for the full year 2024, showcasing a notable performance that exceeded expectations. The company reported a revenue of $293.0 million, reflecting a 6.8% increase compared to the previous year. This growth highlights the company's ability to navigate a competitive market and meet the evolving needs of its customers.
Earnings per share (EPS) also surpassed analyst forecasts, signaling strong operational efficiency and effective cost management. The positive financial results can be attributed to the successful launch of new products and an increase in demand for existing offerings.
The company’s management expressed optimism about future growth, emphasizing their commitment to innovation and expanding their market reach. As Tactile Systems Technology continues to invest in research and development, stakeholders remain hopeful about sustained performance in the coming years. This strong financial showing positions the company well for future opportunities and challenges in the healthcare sector.
MORE NEWS
September 30, 2026 - 21:59
Micron Technology Tops Lofty Fiscal Q4 Goals, Guides Above ViewsMicron Technology exceeded analyst expectations for its fiscal fourth quarter, delivering results that outperformed even the most optimistic projections on Wall Street. The memory chip maker...
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...